Skip to content
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Infectious Disease

Cryptococcus gattii vs. neoformans: What's the Difference?

At a Glance

The main difference between these fungal infections is who they affect. Cryptococcus neoformans mostly infects people with weakened immune systems, while Cryptococcus gattii often infects completely healthy individuals. C. gattii is also more likely to form fungal lumps requiring longer treatment.

When you read your lab report and see Cryptococcus gattii instead of Cryptococcus neoformans, it is completely normal to wonder what this means for your health. Both are types of fungi that cause a serious infection called cryptococcosis, but they behave differently. The main difference is who they infect: C. neoformans usually affects people with weakened immune systems, while C. gattii can often infect entirely healthy people [1][2]. They also live in different parts of the world and can require slight adjustments to how your doctor monitors and treats your infection.

Regardless of the species, you cannot catch this infection from another person. It is acquired by inhaling microscopic fungal spores from the environment.

Who Gets Infected?

The most significant difference between the two species is the type of patient they tend to affect:

  • Cryptococcus neoformans: This is the most common cause of cryptococcosis. It primarily infects people who are immunocompromised (have a weakened immune system) [3]. This includes individuals living with advanced HIV, organ transplant recipients, or people taking heavy immune-suppressing medications.
  • Cryptococcus gattii: While it can infect immunocompromised people, this species is unique because it frequently causes illness in immunocompetent people—meaning those with healthy, fully functioning immune systems [2][1].

Interestingly, researchers have discovered that some seemingly healthy people who get a C. gattii infection may have hidden vulnerabilities in their immune system. For example, some patients produce autoantibodies (proteins that mistakenly attack the body’s own defense systems) that neutralize a crucial immune signaling protein, making it harder for the body to clear the fungus [4].

Where Are They Found?

Both fungi live in the environment, but their geographic maps and preferred homes look slightly different:

  • C. neoformans is considered a global pathogen. It can be found in soil and bird droppings almost anywhere in the world.
  • C. gattii has historically been found in tropical and subtropical regions (like parts of Australia and South America) [5]. However, it is also well-known for thriving in specific temperate regions, most notably the Pacific Northwest of the United States and Canada. It is heavily associated with specific trees, such as eucalyptus and Douglas firs [6].

How Does It Affect the Body?

While both species can cause lung infections (pneumonia) or spread to the brain to cause meningitis, C. gattii has a few unique clinical features:

  • Cryptococcomas: C. gattii is more likely to clump together and form solid lumps or nodules of fungus called cryptococcomas in the lungs or brain [7].
  • IRIS Risk: If the infection reaches the central nervous system (the brain and spinal cord), C. gattii carries a higher risk of triggering Immune Reconstitution Inflammatory Syndrome (IRIS) [8]. IRIS is a condition where your immune system aggressively overreacts to the dead or dying fungus during treatment, causing dangerous inflammation. Warning signs include worsening headaches, new or returning fevers, or sudden confusion. If you experience these symptoms, contact your doctor immediately.
  • Mortality: Despite the risk of IRIS and large fungal masses, studies have shown that patients with C. gattii actually have a lower overall mortality (death) rate compared to those with C. neoformans [8].

Treatment and Monitoring Adjustments

Because C. gattii behaves differently, your medical team may adjust your care plan in a few ways:

  • Susceptibility Testing: Some strains of C. gattii can be less sensitive to common antifungal medications, like fluconazole [9][10]. Your doctor may run tests on your specific fungal sample to make sure you are getting the most effective drug.
  • Length of Treatment: Because C. gattii can form stubborn cryptococcomas, these masses may respond more slowly to medicine. Standard treatment for cryptococcosis often lasts 6 to 12 months, but your doctor might recommend an even longer course to ensure the C. gattii lumps fully shrink [7].
  • Surgery: In rare cases where a cryptococcoma in the lung or brain is very large or doesn’t respond well to antifungal drugs, surgical removal might be necessary [7].

Common questions in this guide

Can a healthy person get a Cryptococcus infection?
Yes. While Cryptococcus neoformans usually affects people with weakened immune systems, Cryptococcus gattii frequently infects individuals who are otherwise healthy and have fully functioning immune systems.
Where is Cryptococcus gattii found?
Cryptococcus gattii is commonly found in tropical and subtropical regions, as well as temperate areas like the Pacific Northwest of the United States and Canada. It is often linked to specific trees, such as eucalyptus and Douglas firs.
What is a cryptococcoma?
A cryptococcoma is a solid lump or nodule of fungus that can form in the lungs or brain. They are much more likely to occur with Cryptococcus gattii infections and sometimes require surgery if they do not shrink with medication.
Why might my treatment for Cryptococcus gattii take longer?
Cryptococcus gattii is prone to forming stubborn fungal lumps that respond slowly to medication. While standard treatment lasts 6 to 12 months, your doctor may extend your therapy to ensure these masses completely disappear.
What are the signs of IRIS during cryptococcosis treatment?
Immune Reconstitution Inflammatory Syndrome (IRIS) is a dangerous condition where your immune system aggressively overreacts to dying fungus during treatment. Warning signs include new or returning fevers, worsening headaches, and sudden confusion.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did the lab perform susceptibility testing to ensure my prescribed antifungal medication is highly effective against this specific strain of Cryptococcus gattii?
  2. 2.Did my imaging scans show any signs of cryptococcomas in my lungs or brain, and how will we monitor them during treatment?
  3. 3.Given my diagnosis, what is my expected treatment timeline, and how often will I need follow-up scans?
  4. 4.What specific symptoms should I watch for that might indicate excessive inflammation or IRIS?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (10)
  1. 1

    Cryptococcosis caused by cryptococcus gattii: 2 case reports and literature review.

    Xue X, Deng H, Zhao L, et al.

    Medicine 2020; (99(50)):e23213 doi:10.1097/MD.0000000000023213.

    PMID: 33327239
  2. 2

    Pulmonary Fungal Infections in Immunocompetent Patients.

    Arenas-Jiménez JJ, Franquet T, Rojas-Varela R, et al.

    Journal of thoracic imaging 2026; doi:10.1097/RTI.0000000000000889.

    PMID: 42178892
  3. 3

    Recent Advances in Cryptococcus and Cryptococcosis.

    Firacative C, Trilles L, Meyer W

    Microorganisms 2021; (10(1)) doi:10.3390/microorganisms10010013.

    PMID: 35056462
  4. 4

    Autoantibodies neutralizing GM-CSF in HIV-negative Colombian patients infected with Cryptococcus gattii and C. neoformans.

    Arango-Franco CA, Rojas J, Firacative C, et al.

    Research square 2024; doi:10.21203/rs.3.rs-3873029/v1.

    PMID: 38313298
  5. 5

    Continental Drift and Speciation of the Cryptococcus neoformans and Cryptococcus gattii Species Complexes.

    Casadevall A, Freij JB, Hann-Soden C, Taylor J

    mSphere 2017; (2(2)) doi:10.1128/mSphere.00103-17.

    PMID: 28435888
  6. 6

    The mycobiome of Australian tree hollows in relation to the Cryptococcus gattii and C. neoformans species complexes.

    Schmertmann LJ, Irinyi L, Malik R, et al.

    Ecology and evolution 2019; (9(17)):9684-9700 doi:10.1002/ece3.5498.

    PMID: 31534685
  7. 7

    Cryptococcus gattii infection in an immunocompetent host in Greece.

    Andreou M, Cogliati M, Kolonitsiou F, et al.

    Medical mycology case reports 2020; (27()):1-3 doi:10.1016/j.mmcr.2019.12.002.

    PMID: 31867171
  8. 8

    Management, Outcomes, and Predictors of Mortality of Cryptococcus Infection in Patients Without HIV: A Multicenter Study in 46 Hospitals in Australia and New Zealand.

    Coussement J, Heath CH, Roberts MB, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2025; (80(4)):817-825 doi:10.1093/cid/ciae630.

    PMID: 39692570
  9. 9

    Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.

    Gutch RS, Nawange SR, Singh SM, et al.

    Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] 2015; (46(4)):1125-33.

    PMID: 26691471
  10. 10

    Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.

    Carvajal SK, Melendres J, Escandón P, Firacative C

    Microbiology spectrum 2023; (11(4)):e0140323 doi:10.1128/spectrum.01403-23.

    PMID: 37341584

This page explains the differences between Cryptococcus species for educational purposes only. Always consult an infectious disease specialist or your healthcare provider for diagnosis and treatment decisions.

Get notified when new evidence is published on Cryptococcosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.